Second-line treatment of advanced measurable ovarian cancer with iproplatin: A Southwest oncology group study

Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts

“…Figure 3b. The four lines with acquired resistance to the platinum (II) agents cisplatin (PXN/87C, PXN/95C and PXN/109T/CC) and carboplatin (HX/l lOP) showed a general cross-resistance to the other agents studied (Figures 1-3 (Gore et al, 1989;Eisenhauer et al, 1990) and cisplatin followed by iproplatin (Sessa et al, 1988;Weiss et al, 1991). These cross-over studies strongly suggest that all three agents essentially share cross-resistance with each other.…”

Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts

“…Figure 3b. The four lines with acquired resistance to the platinum (II) agents cisplatin (PXN/87C, PXN/95C and PXN/109T/CC) and carboplatin (HX/l lOP) showed a general cross-resistance to the other agents studied (Figures 1-3 (Gore et al, 1989;Eisenhauer et al, 1990) and cisplatin followed by iproplatin (Sessa et al, 1988;Weiss et al, 1991). These cross-over studies strongly suggest that all three agents essentially share cross-resistance with each other.…”

High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy

“…Four reports support the use of second-line platinum-based salvage therapy in platinum-sensitive, but not platinumresistant, tumors [24][25][26][27]. All four suggest that patients who respond to platinum-based therapy initially and relapse after a significant platinum-free interval entertain a high likelihood of responding again to platinum-based treatment.…”

Characterization of global research trends and prospects on platinum-resistant ovarian cancer: a bibliometric analysis

“…The two studies that were originally used to define “platinum resistance” determined disease recurrence based on clinical symptoms, clinically detectable disease, and/or radiological evidence of disease recurrence ( 32 , 33 ). During the first two years following the official coinage of the term “PROC,” only 16 articles were published.…”

Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts

“…Figure 3b. The four lines with acquired resistance to the platinum (II) agents cisplatin (PXN/87C, PXN/95C and PXN/109T/CC) and carboplatin (HX/l lOP) showed a general cross-resistance to the other agents studied (Figures 1-3 (Gore et al, 1989;Eisenhauer et al, 1990) and cisplatin followed by iproplatin (Sessa et al, 1988;Weiss et al, 1991). These cross-over studies strongly suggest that all three agents essentially share cross-resistance with each other.…”

High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy

“…Four reports support the use of second-line platinum-based salvage therapy in platinum-sensitive, but not platinumresistant, tumors [24][25][26][27]. All four suggest that patients who respond to platinum-based therapy initially and relapse after a significant platinum-free interval entertain a high likelihood of responding again to platinum-based treatment.…”

Characterization of global research trends and prospects on platinum-resistant ovarian cancer: a bibliometric analysis

“…The two studies that were originally used to define “platinum resistance” determined disease recurrence based on clinical symptoms, clinically detectable disease, and/or radiological evidence of disease recurrence ( 32 , 33 ). During the first two years following the official coinage of the term “PROC,” only 16 articles were published.…”

Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts

“…Figure 3b. The four lines with acquired resistance to the platinum (II) agents cisplatin (PXN/87C, PXN/95C and PXN/109T/CC) and carboplatin (HX/l lOP) showed a general cross-resistance to the other agents studied (Figures 1-3 (Gore et al, 1989;Eisenhauer et al, 1990) and cisplatin followed by iproplatin (Sessa et al, 1988;Weiss et al, 1991). These cross-over studies strongly suggest that all three agents essentially share cross-resistance with each other.…”

High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy

“…Four reports support the use of second-line platinum-based salvage therapy in platinum-sensitive, but not platinumresistant, tumors [24][25][26][27]. All four suggest that patients who respond to platinum-based therapy initially and relapse after a significant platinum-free interval entertain a high likelihood of responding again to platinum-based treatment.…”

Characterization of global research trends and prospects on platinum-resistant ovarian cancer: a bibliometric analysis

“…The two studies that were originally used to define “platinum resistance” determined disease recurrence based on clinical symptoms, clinically detectable disease, and/or radiological evidence of disease recurrence ( 32 , 33 ). During the first two years following the official coinage of the term “PROC,” only 16 articles were published.…”